Bullous pemphigoid latest conquest for Dupixent

Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) all-conquering inflammatory diseases drug Dupixent (dupilumab) has shown its worth in another disease.

Dupixent has already received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease. More than one million patients are being treated with the product globally.

Now it has shown its potential in bullous pemphigoid (BP), meeting the primary and all key secondary endpoints in a pivotal study evaluating its investigational use in adults with moderate-to-severe disease.